2nd Circ. On Hunt For Antitrust Theory In $2B Takeda Action
By Pete Brush ( September 16, 2016, 4:38 PM EDT) -- The fate of an antitrust action claiming spurious Takeda Pharmaceutical Co. patent claims cost diabetes patients $2 billion by delaying generic versions of Actos appeared to rest Friday on the Second Circuit's ability to read a cogent theory of anticompetitive conduct into a long 2014 complaint that was not amended after the drugmaker's dismissal motion....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.